IMVT

Business Context and Reporting Period

Immunovant, Inc. (IMVT) is a clinical-stage immunology company focused on developing anti-FcRn therapies, primarily its lead asset IMVT-1402 and batoclimab, for autoimmune diseases. This Form 10-Q covers the quarterly period ended December 31, 2025, and the nine months ended on that date. The company has not generated any revenue to date and relies on equity financing to fund operations.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt on its balance sheet as of December 31, 2025.

Material Changes vs. Prior Period

• Revenue: Remained at $0, consistent with the prior year.
• Net Loss: For the nine months ended December 31, 2025, net loss increased by $50.4 million (16.4%) compared to the prior year period, driven by higher R&D expenses.
• R&D Expenses: Increased by $47.1 million (17.6%) for the nine-month period. This was primarily due to the initiation of potentially registrational trials for IMVT-1402 in endocrine, rheumatology, and dermatology indications, and increased personnel costs.
• G&A Expenses: Increased by $1.9 million (3.4%) for the nine-month period, mainly due to higher personnel-related expenses.
• Liquidity: Cash and cash equivalents increased by $280.6 million during the nine-month period, largely due to a December 2025 underwritten offering of 26.2 million shares which raised net proceeds of $543.6 million.

Guidance, Outlook, and Risks

• Outlook: Management expects existing cash of $994.5 million to fund operations through the potential commercial launch of IMVT-1402 in Graves' disease (GD). The company anticipates continuing to incur net losses for the foreseeable future.
• Clinical Milestones:
  • Batoclimab: Top-line results from Phase 3 Thyroid Eye Disease (TED) studies expected in the first half of 2026.
  • IMVT-1402: Top-line results expected for D2T RA and CLE in the second half of 2026; GD, MG, and CIDP results expected in 2027 or 2028.
• Key Risks:
  • HanAll Agreement: The company relies on a license from HanAll Biopharma. Disputes regarding the return of batoclimab rights could lead to arbitration or litigation.
  • Capital Requirements: Future funding may be required; inability to raise capital could force delays in development.
  • Clinical Uncertainty: Clinical trials are expensive and may fail to demonstrate efficacy or safety, delaying or preventing regulatory approval.
• Subsequent Event: In January 2026, the company completed an internal reorganization of intellectual property rights between subsidiaries, expecting a reduction in current income tax expense and foreign net operating losses.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $994.5 million cash balance against the projected burn rate for the multiple ongoing registrational trials.
• HanAll Dispute Status: Monitor developments regarding the potential return of batoclimab rights to HanAll and any resulting legal or financial implications.
• Clinical Trial Enrollment: Track enrollment rates and timelines for the six active IMVT-1402 indications, particularly the registrational trials in GD and D2T RA.
• Manufacturing Commitments: Review the $39.1 million remaining obligation for batoclimab contract manufacturing and its impact on future cash flows.
• Stock-Based Compensation: Assess the impact of the $44.6 million stock-based compensation expense recorded in the nine-month period on future dilution and cash burn.